ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement

ARS Pharmaceuticals (SPRY) announced that the FDA has approved updating the neffy 1 mg prescribing information to remove the age criteria so all children and adults who weigh 33 pounds or more can utilize neffy for the emergency treatment of Type 1 allergic reactions, including anaphylaxis. Prior to the update, pediatric patients needed to meet a weight requirement and be at least four years of age. Additionally, the label update recommends patients carry neffy in the blister packaging or in the neffy carrying case.